Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 15;345(1-2):118-24.
doi: 10.1016/j.jns.2014.07.022. Epub 2014 Jul 18.

ALS-Plus syndrome: non-pyramidal features in a large ALS cohort

Affiliations

ALS-Plus syndrome: non-pyramidal features in a large ALS cohort

Leo McCluskey et al. J Neurol Sci. .

Abstract

Objective: Autopsy studies show widespread pathology in amyotrophic lateral sclerosis (ALS), but clinical surveys of multisystem disease in ALS are rare. We investigated ALS-Plus syndrome, an understudied group of patients with clinical features extending beyond pyramidal and neuromuscular systems with or without cognitive/behavioral deficits.

Methods: In a large, consecutively-ascertained cohort of 550 patients with ALS, we documented atypical clinical manifestations. Genetic screening for C9orf72 hexanucleotide expansions was performed in 343 patients, and SOD1, TARDBP, and VCP were tested in the subgroup of patients with a family history of ALS. Gray matter and white matter imaging was available in a subgroup of 30 patients.

Results: Seventy-five (13.6%) patients were identified with ALS-Plus syndrome. We found disorders of ocular motility, cerebellar, extrapyramidal and autonomic functioning. Relative to those without ALS-Plus, cognitive impairment (8.0% vs 2.9%, p=0.029), bulbar-onset (49.3% vs 23.2%, p<0.001), and pathogenic mutations (20.0% vs 8.4%, p=0.015) were more than twice as common in ALS-Plus. Survival was significantly shorter in ALS-Plus (29.66 months vs 42.50 months, p=0.02), regardless of bulbar-onset or mutation status. Imaging revealed significantly greater cerebellar and cerebral disease in ALS-Plus compared to those without ALS-Plus.

Conclusions: ALS-Plus syndrome is not uncommon, and the presence of these atypical features is consistent with neuropathological observations that ALS is a multisystem disorder. ALS-Plus syndrome is associated with increased risk for poor survival and the presence of a pathogenic mutation.

Keywords: Amyotrophic lateral sclerosis; Cognitive; Genetics; Non-neuromuscular; Survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Gray Matter Atrophy and Reduced White Matter Fractional Anisotropy in ALS-plus Compared to those without ALS-plus
Note 1. Panel A: Gray matter atrophy (green) at x=1; Panel B: Gray matter atrophy y=34; Panel C: Reduced fractional anisotropy (red) at x=-10; Panel D: Reduced fractional anisotropy at y=-10 (top), y=-24 (bottom). Vertical white lines indicate location of coronal slices.

Comment in

References

    1. Ludolph AC, Brettschneider J, Weishaupt JH. Amyotrophic lateral sclerosis. Current opinion in Neurology. 2012;25(5):530–5. 10.1097/WCO.0b013e328356d328. - PubMed
    1. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2000;1(5):293–9. - PubMed
    1. Pradat PF, Bruneteau G. Quels sont les diagnostics differentiels et les formes frontières de SLA? Revue Neurologique. 2006;162:4S17–4S24. - PubMed
    1. Sharma R, Hicks S, Berna CM, Kennard C, Talbot K, Turner MR. Oculomotor Dysfunction in Amyotrophic Lateral Sclerosis: A Comprehensive Review. Arch Neurol. 2011 Jul 1;68(7):857–61. 2011. - PubMed
    1. Irwin DJ, McMillan CT, Suh E, Powers JM, Rascovsky K, Wood EM, et al. Myelin oligodendrocyte basic protein and survival in behavioral-variant frontotemporal dementia. submitted. 2014 - PMC - PubMed

Publication types

MeSH terms